Tyrosine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tyrosine: From No Approved Indication to Cauda Equina Syndrome
One-Sentence Summary
Tyrosine currently has no SAHPRA-registered product and no documented original therapeutic indication — it is generally used as a naturally occurring amino acid / nutritional and diagnostic-reagent substance. TxGNN’s top-ranked prediction links it to Cauda Equina Syndrome, but this candidate has 0 clinical trials and 0 publications supporting it, and the underlying rationale explicitly flags the prediction as likely model noise rather than a credible mechanistic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — Tyrosine has no registered indications in the source data; conventionally used as an amino acid supplement/diagnostic reagent, not as a disease-specific therapeutic |
| Predicted New Indication | Cauda Equina Syndrome |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data for Tyrosine is not available in the current evidence pack. Based on general pharmacology, Tyrosine is a non-essential amino acid and a biosynthetic precursor to catecholamines (dopamine, noradrenaline) and thyroid hormones; it has no established role as a disease-modifying therapeutic agent.
For this specific candidate, the evidence pack’s own analysis assesses the mechanistic link as not plausible: Cauda Equina Syndrome is a mechanical neurological emergency caused by nerve root compression, typically requiring urgent surgical decompression. Tyrosine’s role as a neurotransmitter precursor has no established pathophysiological connection to nerve compression. The evidence pack explicitly characterizes this top-ranked result as likely TxGNN prediction noise rather than a genuine repurposing signal, and no clinical trials, ICTRP trials, or literature were found linking the two.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Tyrosine has 0 SAHPRA registrations and is currently not marketed in South Africa. No product listings, dosage forms, or approved indication text are available to summarize.
Safety Considerations
Safety data for this candidate is incomplete. A Blocking-severity data gap has been identified: SAHPRA/TFDA package insert warnings and contraindications are not yet available, which prevents this candidate from completing even the initial (S1) safety screening. No drug interaction records were found (query status: not found).
Please refer to the SAHPRA-approved Professional Information (PI) for safety information once available. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Cauda Equina Syndrome) has no clinical trial, literature, or plausible mechanistic support, and is assessed by the underlying analysis as likely model noise. Combined with a Blocking safety data gap (package insert warnings/contraindications unavailable) and the drug’s unregistered/not-marketed status in South Africa, there is no basis to proceed at this time.
To proceed, the following is needed:
- SAHPRA/TFDA package insert (warnings, contraindications) to clear the Blocking data gap (DG001)
- Confirmed mechanism of action data (DG002)
- If repurposing interest continues, re-evaluate lower-ranked candidates with comparatively more evidence — e.g., hyperthyroidism (L4, 4 trials + 20 publications, though mechanistic direction is “may induce/aggravate” rather than “treat”) and postural orthostatic tachycardia syndrome (L4, indirect catecholamine-precursor rationale) — both still scored Hold pending human review, as none of the top 10 candidates reached an actionable therapeutic evidence tier in this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.